Osimertinib (GMP)

Overview

Osimertinib (AZD-9291; Mereletinib) GMP is the GMP level of Osimertinib ( HY-15772 ). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP is an inhibitor that selectively targets EGFR T790M and activated EGFR mutants. Osimertinib GMP exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis , as well as inhibition of cancer stemness. Osimertinib GMP suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP can be used in research related to radioresistant glioblastoma and non-small cell lung cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > EGFR | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Ferroptosis

Product Information

• Catalog No.: HY-15772G
• CAS No.: 1421373-65-0
• Molecular Formula: C28H33N7O2
• Molecular Weight: 499.61
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source